Given that the export of nuclear tumour suppressor proteins to the cytoplasm is a potential mechanism to compromise their function, the inhibition of XPO1’s nuclear export function is an attractive target for anticancer therapies that restore nuclear tumour suppressor activity by preventing nuclear export [6]. This evidence concerns the gene XPO1 and neoplasm.